Form 4: Pfizer Director James C. Smith Reports Acquisition of Phantom Stock Units

Director James C. Smith reports acquisition of phantom stock units in Pfizer Inc. through a nonfunded deferred compensation plan.

Summary

• On April 28, 2025, James C. Smith, a director of Pfizer Inc., filed a Form 4 with the SEC.
• The report details the acquisition of 8,999 phantom stock units on April 24, 2025, at a price of $22.78 per unit.
• These units were granted pursuant to Pfizer's Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Smith now beneficially owns 152,563.319 phantom stock units.
• The phantom stock units represent deferred director's compensation and will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing indicating standard compensation practices. It doesn't suggest any significant positive or negative implications for the company's financial health or future prospects.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The Nonfunded Deferred Compensation and Unit Award Plan is a common method of compensating non-employee directors.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

Reporting of beneficial ownership changes by company insiders is a standard practice governed by SEC regulations, ensuring transparency in the market.

Comparison to Industry Standards

• Deferred compensation plans, including phantom stock units, are a common component of director compensation packages in publicly traded companies like Pfizer.
• Companies such as Johnson & Johnson and Merck also utilize similar deferred compensation plans to align director interests with shareholder value.

Stakeholder Impact

• The acquisition of phantom stock units aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term performance.

Key Dates

Keywords

Form 4, Pfizer, Director, Phantom Stock Units, Deferred Compensation, Beneficial Ownership, SEC